Cipla Limited has posted net profit of Rs. 525.65 crores for the period ended March 31, 2023 as against net profit of Rs. 800.96 crores for the period ended December 31, 2022. The company posted net profit of Rs.362.07 crores for the period ended March 31, 2022.

Cipla has reported total income of Rs. 5873.93 crores during the period ended March 31, 2023 as compared to Rs. 5924.53 crores during the period ended December 31, 2022. The company reported total income of Rs.5324.35 crores during the period ended March 31, 2022.

For the Financial Year ended March 31, 2023, Cipla has reported total income of Rs.23228.57 croresas compared to Rs.22044.25 crores during the Financial Year ended March 31, 2022.

The company has posted net profit of Rs.2801.91 crores for the Financial Year ended March 31, 2023 as against net profit of Rs.2516.75 crores for the Financial Year ended March 31, 2022.

“I am pleased to share that we continue to make significant progress across our focused markets. In FY23, we recorded highest ever revenue with EBITDA crossing INR 5,000 Cr for the first time. Our One-India business continued the double-digit trajectory growing at 13% ex-Covid during the year led by branded prescription and sustained growth across our acute and chronic therapies. Our continued focus on differentiated portfolio has strengthened our US business which posted highest ever quarterly revenue at $ 204 Mn and $ 733 Mn for FY23. Adjusting for covid, our core operating profitability continues to be strong at ~23% expanding by 100 bps over last year. We are excited for the upcoming year, where we look forward to deepening our leadership in branded markets and expanding our differentiated pipeline in the US,” Umang Vohra, MD and Global CEO, Cipla Ltd, said.